重组肿瘤坏死因子在肾细胞癌中的II期研究:加拿大国家癌症研究所临床试验组的研究。

Journal of immunotherapy : official journal of the Society for Biological Therapy Pub Date : 1992-01-01 DOI:10.1097/00002371-199201000-00008

J Skillings, R Wierzbicki, E Eisenhauer, P Venner, F Letendre, D Stewart, B Weinerman

{"title":"重组肿瘤坏死因子在肾细胞癌中的II期研究:加拿大国家癌症研究所临床试验组的研究。","authors":"J Skillings, R Wierzbicki, E Eisenhauer, P Venner, F Letendre, D Stewart, B Weinerman","doi":"10.1097/00002371-199201000-00008","DOIUrl":null,"url":null,"abstract":"The National Cancer Institute (NCI) Canada Clinical Trials Group conducted a phase II study of recombinant tumor necrosis factor (rTNF) given intravenously daily for 5 days every other week, in measurable metastatic renal cell carcinoma. Two of 26 patients responded with responses lasting greater than 200 days. Toxicity was severe including rigors, fever, headache, fatigue, hypotension, and localized pain. We conclude that rTNF, given as described, has only modest antitumor activity in renal cell carcinoma and produces considerable toxicity. We plan no further studies of rTNF in this disease.","PeriodicalId":77209,"journal":{"name":"Journal of immunotherapy : official journal of the Society for Biological Therapy","volume":"11 1","pages":"67-70"},"PeriodicalIF":0.0000,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00002371-199201000-00008","citationCount":"46","resultStr":"{\"title\":\"A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.\",\"authors\":\"J Skillings, R Wierzbicki, E Eisenhauer, P Venner, F Letendre, D Stewart, B Weinerman\",\"doi\":\"10.1097/00002371-199201000-00008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The National Cancer Institute (NCI) Canada Clinical Trials Group conducted a phase II study of recombinant tumor necrosis factor (rTNF) given intravenously daily for 5 days every other week, in measurable metastatic renal cell carcinoma. Two of 26 patients responded with responses lasting greater than 200 days. Toxicity was severe including rigors, fever, headache, fatigue, hypotension, and localized pain. We conclude that rTNF, given as described, has only modest antitumor activity in renal cell carcinoma and produces considerable toxicity. We plan no further studies of rTNF in this disease.\",\"PeriodicalId\":77209,\"journal\":{\"name\":\"Journal of immunotherapy : official journal of the Society for Biological Therapy\",\"volume\":\"11 1\",\"pages\":\"67-70\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1992-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1097/00002371-199201000-00008\",\"citationCount\":\"46\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of immunotherapy : official journal of the Society for Biological Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/00002371-199201000-00008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of immunotherapy : official journal of the Society for Biological Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/00002371-199201000-00008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 46

摘要

加拿大国家癌症研究所(NCI)临床试验组进行了一项II期研究，重组肿瘤坏死因子(rTNF)每天静脉注射，每隔一周5天，用于可测量的转移性肾细胞癌。26名患者中有2名患者的反应持续时间超过200天。毒性严重，包括僵硬、发热、头痛、疲劳、低血压和局部疼痛。我们的结论是，如上所述，rTNF在肾细胞癌中只有适度的抗肿瘤活性，并产生相当大的毒性。我们不打算进一步研究rTNF在这种疾病中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.

The National Cancer Institute (NCI) Canada Clinical Trials Group conducted a phase II study of recombinant tumor necrosis factor (rTNF) given intravenously daily for 5 days every other week, in measurable metastatic renal cell carcinoma. Two of 26 patients responded with responses lasting greater than 200 days. Toxicity was severe including rigors, fever, headache, fatigue, hypotension, and localized pain. We conclude that rTNF, given as described, has only modest antitumor activity in renal cell carcinoma and produces considerable toxicity. We plan no further studies of rTNF in this disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of immunotherapy : official journal of the Society for Biological Therapy

自引率

0.00%

发文量